CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 26 enrolled
Drug / intervention
Evacetrapib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01908582
NCT01908582Phase 1Completed
CompareCT.gov

Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects

Eli Lilly and Company·interventional·Posted Jul 25, 2013·Updated Oct 3, 2018

In Brief

A Phase 1 clinical trial evaluating Evacetrapib and Rifampin for Healthy Volunteers. Completed, enrolled 26 participants across 1 site.

Detailed Summary

The main purpose of this study is to determine how much evacetrapib gets into the blood stream and how long it takes the body to get rid of it when given with rifampin. The safety and tolerability of the two drugs, given together, will also be evaluated. The study will also look at blood cholesterol levels and levels of a hormone called cortisol before and after taking rifampin. Information about any side effects that may occur will also be collected. For each participant, this study will include 2 periods in fixed order. The study will last approximately 29 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 25, 2013
Enrollment StartJul 1, 2013
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.9 years ago

Interventions

Evacetrapibdrug

Administered orally

Rifampindrug

Administered orally